Announcements Trials
Browse Landscape

Status

No longer available 2

Sponsor Class

OTHER 1NIH 1

Study Type

Expanded_access 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × Expanded_access × aldesleukin × Clear all
NCT04135092 2020-09-04

Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

National Institutes of Health Clinical Center (CC)

No longer available
NCT01005537 2010-08-06

Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma

Fred Hutchinson Cancer Center

No longer available
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡